Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2-14).

Date publication

février 2020

Journal

Breast (Edinburgh, Scotland)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr JOUANNAUD Christelle

Tous les auteurs :
Penault-Llorca F, Kwiatkowski F, Arnaud A, Levy C, Leheurteur M, Uwer L, Derbel O, Le Rol A, Jacquin JP, Jouannaud C, Quenel-Tueux N, Girre V, Foa C, Guardiola E, Lortholary A, Catala S, Guiu S, Valent A, Boinon D, Lemonnier J, Delaloge S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31790959

Résumé

Genomic tests can identify ER-positive HER2-negative localized breast cancer patients who may not benefit from adjuvant chemotherapy. Such tests seem especially interesting in "intermediate" clinico-pathological risk categories. The psychological impact of the decision uncertainty in these women remains largely unexplored. We assessed the clinical and psychological impact of EndoPredict® (EpClin), a clinico-genomic test, in these patients.

Mots clés

Breast cancer, Chemotherapy, EndoPredict®, Genomic test, Patient reported outcomes

Référence

Breast. 2020 Feb;49:132-140